Royalty Pharma
(NASDAQ:RPRX)
$30.45
0[0.00%]
At close: Mar 27
$30.45
0[0.00%]
PreMarket: 4:00PM EDT
Consensus Rating1
Buy
Highest Price Target1
$60.00
Lowest Price Target1
$42.00
Consensus Price Target1
$50.75

Royalty Pharma Stock (NASDAQ:RPRX), Analyst Ratings, Price Targets, Predictions

Royalty Pharma PLC has a consensus price target of $50.75, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Goldman Sachs, and Morgan Stanley on February 20, 2024, February 20, 2024, and November 9, 2023. With an average price target of $49.67 between JP Morgan, Goldman Sachs, and Morgan Stanley, there's an implied 63.11% upside for Royalty Pharma PLC from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Oct 23
1
Nov 23
1
Feb
2
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JP Morgan
Goldman Sachs
Morgan Stanley
Tigress Financial
UBS

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Royalty Pharma

date
▲▼
ticker
▲▼
Buy Now
Company
▲▼
Current price
▲▼
Upside/Downside
▲▼
Analyst Firm
▲▼
Analyst & % Accurate
▲▼
Price Target Change
▲▼
Rating Change
▲▼
Previous / Current Rating
▲▼
Get Alert
02/20/2024RPRXBuy Now
Royalty Pharma
$30.4537.93%JP Morgan
Chris Schott
$45 → $42MaintainsOverweightGet Alert
02/20/2024RPRXBuy Now
Royalty Pharma
$30.4564.2%Goldman Sachs
Chris Shibutani
$56 → $50MaintainsBuyGet Alert
11/09/2023RPRXBuy Now
Royalty Pharma
$30.4587.19%Morgan Stanley
Terence Flynn
$54 → $57MaintainsOverweightGet Alert
10/11/2023RPRXBuy Now
Royalty Pharma
$30.4577.34%Morgan Stanley
Terence Flynn
$53 → $54MaintainsOverweightGet Alert
08/09/2023RPRXBuy Now
Royalty Pharma
$30.4574.06%Morgan Stanley
Terence Flynn
$52 → $53MaintainsOverweightGet Alert
07/11/2023RPRXBuy Now
Royalty Pharma
$30.4570.77%Morgan Stanley
Terence Flynn
$52 → $52ReiteratesOverweight → OverweightGet Alert
05/10/2023RPRXBuy Now
Royalty Pharma
$30.4570.77%Morgan Stanley
Terence Flynn
$50 → $52MaintainsOverweightGet Alert
04/10/2023RPRXBuy Now
Royalty Pharma
$30.4564.2%Morgan Stanley
Terence Flynn
$48 → $50MaintainsOverweightGet Alert
04/06/2023RPRXBuy Now
Royalty Pharma
$30.4597.04%Tigress Financial
Ivan Feinseth
$57 → $60Reiterates → BuyGet Alert
02/16/2023RPRXBuy Now
Royalty Pharma
$30.4557.64%UBS
Ashwani Verma
$51 → $48MaintainsBuyGet Alert
12/06/2022RPRXBuy Now
Royalty Pharma
$30.4567.49%Morgan Stanley
Terence Flynn
$54 → $51MaintainsOverweightGet Alert
11/09/2022RPRXBuy Now
Royalty Pharma
$30.4577.34%Morgan Stanley
Terence Flynn
$51 → $54MaintainsOverweightGet Alert
10/18/2022RPRXBuy Now
Royalty Pharma
$30.4570.77%JP Morgan
Chris Schott
$50 → $52MaintainsOverweightGet Alert
08/08/2022RPRXBuy Now
Royalty Pharma
$30.4567.49%Morgan Stanley
Terence Flynn
$48 → $51MaintainsOverweightGet Alert
07/14/2022RPRXBuy Now
Royalty Pharma
$30.4587.19%Tigress Financial
Ivan Feinseth
$52 → $57MaintainsBuyGet Alert
06/14/2022RPRXBuy Now
Royalty Pharma
$30.4554.35%UBS
Ashwani Verma
→ $47Initiates → BuyGet Alert
05/13/2022RPRXBuy Now
Royalty Pharma
$30.4574.06%Scotiabank
Adam Buckham
→ $53Initiates → OutperformGet Alert
04/27/2022RPRXBuy Now
Royalty Pharma
$30.4583.91%Goldman Sachs
Chris Shibutani
→ $56Initiates → BuyGet Alert
04/14/2022RPRXBuy Now
Royalty Pharma
$30.4564.2%JP Morgan
Chris Schott
→ $50UpgradeNeutral → OverweightGet Alert

FAQ

Q

What is the target price for Royalty Pharma (RPRX)?

A

The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by JP Morgan on February 20, 2024. The analyst firm set a price target for $42.00 expecting RPRX to rise to within 12 months (a possible 37.93% upside). 9 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Royalty Pharma (RPRX)?

A

The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by JP Morgan, and Royalty Pharma maintained their overweight rating.

Q

When was the last upgrade for Royalty Pharma (RPRX)?

A

The last upgrade for Royalty Pharma PLC happened on April 14, 2022 when JP Morgan raised their price target to $50. JP Morgan previously had a neutral for Royalty Pharma PLC.

Q

When was the last downgrade for Royalty Pharma (RPRX)?

A

There is no last downgrade for Royalty Pharma.

Q

When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on February 20, 2024 so you should expect the next rating to be made available sometime around February 20, 2025.

Q

Is the Analyst Rating Royalty Pharma (RPRX) correct?

A

While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $45.00 to $42.00. The current price Royalty Pharma (RPRX) is trading at is $30.45, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch